FDA Approves Oral Formulation of Wegovy Weight-Loss Drug

FDA Approves Oral Wegovy for Weight Management

The U.S. Food and Drug Administration (FDA) has granted approval for an oral formulation of the weight-loss medication Wegovy. This approval was announced by pharmaceutical company Novo Nordisk.

This marks the first instance of an oral medication specifically approved by the FDA for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity.

Novo Nordisk, the Danish manufacturer of Wegovy, stated that the once-daily pill offers a convenient alternative to the existing injectable version. The company indicated that the oral form is designed to provide similar weight loss efficacy as the injectable administration.

Prior to this, Wegovy had received FDA approval specifically for weight loss indications. Other medications, such as Ozempic, which shares similar active ingredients and effects, were initially approved primarily for the treatment of Type 2 diabetes.